This study demonstrated that SOAT1 is a potential biomarker and therapeutic target in NAFLD-HCC and SOAT1-targeting inhibitors are expected to be the potential new therapeutic treatment for HCC. Here, SOAT1 is linked to metabolic dysfunction-associated steatotic liver disease.